New hope for tough leukemia? early trial of ABBV-453 begins
NCT ID NCT06291220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental drug called ABBV-453, given with another cancer drug (obinutuzumab), in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. About 60 participants will receive the drugs and be monitored for side effects, drug levels in the blood, and any changes in their disease. The main goal is to find a safe dose and see how the body handles the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-453 (an investigational drug) combined with obinutuzumab (a cancer antibody)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat CLL or SLL.
- What could go wrong
- This is a very early Phase 1 trial with only 4 participants so far, focused on safety and dosing. It may not lead to an effective treatment, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health /ID# 265136
Charlotte, North Carolina, 28204-2963, United States
-
Austin Health /ID# 256776
Heidelberg, Victoria, 3084, Australia
-
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 263062
Perugia, 06156, Italy
-
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 263433
Berlin, 12203, Germany
-
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 267158
Irvine, California, 92618, United States
-
City of Hope /ID# 253904
Duarte, California, 91010, United States
-
Duplicate_Duke Cancer Center /ID# 258707
Durham, North Carolina, 27710-3000, United States
-
Gold coast University Hospital /ID# 255785
Southport, Queensland, 4215, Australia
-
Hadassah Medical Center-Hebrew University /ID# 254721
Jerusalem, Jerusalem, 91120, Israel
-
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263065
Bologna, 40138, Italy
-
IRCCS Ospedale San Raffaele /ID# 263064
Milan, Milano, 20132, Italy
-
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 264622
Billings, Montana, 59102, United States
-
MD Anderson Cancer Center /ID# 253713
Houston, Texas, 77030, United States
-
Royal Perth Hospital /ID# 256464
Perth, Western Australia, 6000, Australia
-
Royal Prince Alfred Hospital /ID# 263129
Sydney, New South Wales, 2050, Australia
-
The Chaim Sheba Medical Center /ID# 254383
Ramat Gan, Tel Aviv, 5265601, Israel
-
Universitaetsklinikum Halle (Saale) /ID# 263299
Halle, Saxony-Anhalt, 06120, Germany
-
Universitaetsklinikum Hamburg-Eppendorf /ID# 263730
Hamburg, 20246, Germany
-
Universitaetsklinikum Schleswig-Holstein - Campus Kiel /ID# 263150
Kiel, Schleswig-Holstein, 24105, Germany
-
Universitaetsklinikum Ulm /ID# 263148
Ulm, Baden-Wurttemberg, 89081, Germany
-
Yitzhak Shamir Medical Center /ID# 257626
Ẕerifin, Central District, 70300, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?